Contact this trialFirst, we need to learn more about you.
Alkylating Agent
Trilaciclib + Lurbinectedin for Small Cell Lung Cancer
Recruiting1 awardPhase 2
Chapel Hill, North Carolina
This trial looks at how a drug (Trilaciclib) combined with another (Lurbinectedin) affects a type of lung cancer (SCLC). The goal is to reduce side effects and improve the effectiveness of the combination.
Fill-in a few details and create your profileHaving a profile will help us send you recommended trials and speed up your application in the future.
We will keep your details privateWe won’t share unless you give us permission. By completing this form you agree to our privacy policy
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.